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Abstract: Matrix metalloproteinase 2 (MMP-2) activation has been described as a "master switch" which 
triggers tumor spread and metastatic progression. We show here that type IV collagen, a major component of 
basement membranes, promotes MMP-2 activation by HT1080 cells. When plated on plastic, HT1080 cells con-
stitutively processed the 66-kDa pro-MMP-2 into a 62-kDa intermediate activated form, most probably through a 
membrane type (MT) 1 MMP-dependent mechanism. In the presence of type IV collagen, part of this 
intermediate form was further processed to fully activated 59-kDa MMP-2. This activation was prevented by 
tissue inhibitor of MMP (TIMP)-2 and a broad-spectrum hydroxamic acid-based synthetic MMP inhibitor 
(GI129471). Type IV collagen-mediated pro-MMP-2 activation did not involve either a transcriptional 
modulation of MMP-2, MT1-MMP, or TIMP-2 expression nor any alteration of MT1-MMP protein synthesis or 
processing. An inverse relationship between MMP-2 activation and the concentration of secreted TIMP-2 was 
observed. This is consistent with our previous report that TIMP-2 degradation is probably linked to the MT1-
MMP-dependent MMP-2 activation mechanism. Because invasive tumor cells must breach basement membranes 
at different steps of the metastatic dissemination, the ability of HT1080 cells to activate pro-MMP-2 in the 




The active degradation of the basement membrane (BM) is required for tumor invasion and subsequent 
metastatic dissemination [1]. Indeed, BM are present at key points in the metastatic cascade. Escape of malignant 
cells from the primary tumor in epithelial neoplasias, intravasation and extravasation during hematogenous 
dissemination, and perineural and muscular invasion require BM breaching by proteolytic degradation [2-4]. 
Accordingly, interactions between tumor cells and the ECM have emerged as pivotal events of the metastatic 
phenotype. 
Among proteinases, including serine proteinases, cysteine proteinases, and matrix metalloproteinases (MMPs), 
that have been implicated in tumor cell invasion process [5], MMPs appear to be primarily responsible for much 
of the extracellular matrix (ECM) degradation observed during this process. Due to its unusual ability to cleave 
and degrade triple-helical type IV collagen (the major structural component of the BM), MMP-2 (also known as 
gelatinase A) overexpres-sion by tumor cells and/or their associated stroma was considered as a key event during 
tumor progression and metastasis [6, 7]. Nevertheless, overproduction of the proenzyme is not sufficient for the 
acquisition of an invasive phenotype [8]. Indeed, most MMPs are produced as latent zymogens which require a 
proteolytic processing of their N-terminal region to gain catalytic activity. This activity is further controlled by a 
family of specific endogenous tissue inhibitors of MMPs: the TIMPs [9]. In this context, the close association 
observed between MMP-2 activation and metastatic progression in various tumors [10-12] suggests that MMP-2 
activation represents a "master switch" triggering tumor spread. 
MMP-2 activation is mediated by a membrane-associated mechanism that can be induced in vitro by tumor 
necrosis factor-α, concanavalin A (ConA), cytochalasin D, and phorbol esters such as tetradecanoylphorbol 13-
ace-tate (TPA) [13-21]. Sato and co-workers have identified MT1-MMP (membrane type 1 MMP or MMP-14): 
a MMP possessing a hydrophobic C-terminal transmembrane domain, which is considered as a physiological 
MMP-2 activator [22-25]. The active form of MT1-MMP, which is generated through a furin-dependent 
mechanism [26, 27], binds TIMP-2 through the interaction of the N-terminal domains of each protein, thereby 
docking soluble TIMP-2 to the cell surface [20, 28-30]. This bimolecular complex subsequently functions as a 
receptor for the secreted pro-MMP-2, through interactions of their C-terminal domains, thus forming a MT1-
MMP/TIMP-2/MMP-2 ternary complex. In the presence of uncomplexed active MT1-MMP, the prodomain of 
plasma membrane-bound MMP-2 is cleaved between Asn37 and Leu38, thus generating a 62-kDa intermediate 
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activated form. When present at a sufficiently high concentration on the cell surface, this intermediate is further 
processed to the fully activated 59-kDa MMP-2 by an intermolecular auto lytic cleavage between Asn80 and 
Tyr81 [31]. Alternatively, this second cleavage can be achieved through the action of plasmin [32]. However, the 
mechanisms regulating this activation process in vivo remain uncertain. 
Proteins of the ECM, such as collagens, fibronectin, and laminin, have dynamic functions in the regulation of a 
number of cellular mechanisms including cell adhesion, spreading, differentiation, and migration as well as cell 
death [33-35]. Therefore, cell-matrix interactions are likely to play significant roles in the regulation of cellular 
proteolysis [36]. Accordingly, different reports have emphasised the involvement of ECM components including 
fibronectin, bone matrices proteins such as osteopontin and bone sialoprotein [37, 38], and type I collagen [39-
44] in the induction of pro-MMP-2 activation. 
In the present study, we have investigated the potential influence of different ECM components on pro-MMP-2 
activation by a human fibrosarcoma cell line (HT1080) and compared it with ConA- and TPA-induced activation 
mechanisms. 
MATERIAL AND METHODS 
Cell culture. 
 HT1080 human fibrosarcoma were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% (v/v) heat-inactivated fetal calf serum (FCS), penicillin-streptomycin (100 IU/ml-100 µg/ml), 2 mM 
glutamine, and 10 mM Hepes buffer at 37°C in a humid atmosphere (5% CO2-95% air). All culture reagents 
were purchased from Gibco-Life Technologies (Merelbeke, Belgium). 
Human recombinant TIMP-2 (rTIMP-2) was obtained from CHO cells transfected with pDSRa2 vector 
containing human TIMP-2 cDNA. rTIMP-2 was purified as described [45]. The broad-spectrum synthetic MMP 
inhibitor GI129471 [46] was prepared as 10 mM stock solution in dimethyl sulfoxide (DMSO) and used at final 
concentrations ranging from 1 to 1000 nM in 0.1% DMSO. 
Coating of culture wells with ECM components. 
 Laminin and fibronectin were purified from Engelbreth-Holm-Swarm tumors [47] and from human plasma by 
gelatin affinity chromatography [48]. Type I collagen was prepared from fetal calf skin [49] and type IV collagen 
was purified from human placenta (kindly provided by H. W. Krell, Boehringer Mannheim, Penzberg, 
Germany). 
Ninety-six well plates (Falcon, Becton-Dickinson, Meylan, France) were coated (100 µl/well) with the different 
ECM components [diluted at 10-600 µg/ml in phosphate-buffered saline (PBS)] or PBS alone (control). Coats 
were left to air dry overnight in a laminar flow hood under UV light. Before use, coated wells were washed twice 
with water and incubated for 1 h in serum-free DMEM at 37°C. 
Preparation of conditioned media and total cell extracts. 
 Cells growing exponentially in T-75 flasks (Nunc, Roskilde, Denmark) were harvested by trypsin-EDTA 
treatment, washed with 10% FCS-containing medium, and allowed to recover from trypsinisation for at least 30 
min at 37°C. Cells were then washed twice in serum-free DMEM and diluted in the same medium supplemented 
with 0.1% bovine serum albumin (BSA, fraction V, Sigma, Bornem, Belgium) to a density of 3 x 105 cells/ml. 
This cell suspension (200 µl/well) was plated into ECM-coated or PBS-treated wells (see above). Cells plated in 
PBS-treated wells were subsequently supplemented with serum-free DMEM (untreated control), ConA (final 
concentration, 30 µg/ml; Boehringer Mannheim, Mannheim, Germany), or TPA (final concentration, 10 ng/ml; 
Sigma). The conditioned media were collected after different incubation times and stored frozen at -20°C. The 
resulting cell monolayers were washed once with 100 µl serum-free DMEM and extracted with 50 µl of Ripa 
buffer [50 mM Tris-HC1, pH 7.4; 150 mM NaCl; 1% Nonidet P40; 1% Triton X-100; 1% sodium deoxycholate; 
0.1% sodium dodecyl sulfate (SDS); 5 mM iodoacetamide; 2 mM phenylmethylsulfonyl fluoride (PMSF)] for 2 
h at 4°C. Alternatively (for ELISA), extraction was performed by son-ication (10 s, 100 Hz) in 100 µl of PBS 
supplemented with 2 mM PMSF. 
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Gelatin zymography.  
Analysis of gelatinolytic activities in conditioned media and total cell extracts was performed by gelatin 
zymography as previously described [27], 
The relative proportions of the gelatinolytic bands corresponding to the different forms of gelatinase A were 
evaluated by scanning densitometry using a GS-700 imaging densitometer (Bio-Rad, Hercules, CA) equipped 
with Molecular Analyst software. Results were expressed as relative percentages of total gelatinase A activity. 
Western blot analysis for MT1-MMP. 
 Samples of total cell extracts were analyzed using two distinct monoclonal antibodies (mAbs): mAb IE12 
directed against the N-terminal prodomain of MT1-MMP and mAb 2D7 against the hemopexin-like domain of 
MT1-MMP (kindly provided by P. Basset, IGBMC, Illkirch, France) as previously described [27], 
Isolation of RNA and Northern blot analysis.  
Total RNA was extracted from the cell monolayers by RNAzol B treatment (Biogenesis, Bournemouth, UK). An 
aliquot of RNA (15 µg) was electropho-resed through agarose gels containing 10% formamide and transferred 
onto a nylon membrane (Hybond-N, Amersham, Gent, Belgium). The membrane was hybridized with MMP-2, 
MT1-MMP, TIMP-1, and TIMP-2 cDNA probes labeled with 32P using random priming synthesis (Boehringer 
Mannheim). The membrane was re-hybridised to a human 28S-rRNA oligonucleotide probe (Clontech, Palo 
Alto, CA), which served as an internal control. The amounts of the different transcripts were quantified by 
densitometric analysis of autoradiographs of the Northern blots. All results were corrected for RNA loading as a 
function of the densitometric data obtained for the 28S-rRNA signals. 
TIMP-2 quantification by ELISA. 
 TIMP-2 concentrations in conditioned media and total cell extracts were determined using a sandwich ELISA as 
described [50]. Briefly, rTIMP-2 (see above) was used to raise polyclonal antibodies in rabbit (RA Abs) and in 
embryonated chicken eggs (SMI Abs). The specific anti-rTIMP-2 IgGs from chicken were purified by 
ammonium sulfate precipitation [51]. RA pAbs were purified by affinity chromatography. RA Abs were 
adsorbed onto Maxisorp 96-well plates (Nunc) by overnight incubation at 4°C. Wells were subsequently 
saturated overnight at 4°C with 100 µl of PBS buffer supplemented with 3% BSA and 0.05% Tween 20. Test 
samples (50 µl) were added to each well and incubated overnight at 4°C. After three washes with 200 µl of PBS-
0.05% Tween 20 and an incubation with the SMI Abs for 1 h at 37°C, bound TIMP-2 was revealed using 
peroxidase-conjugated rabbit anti-chicken IgGs (Organon Teknica, Turnhout, Belgium) for 1 h at 37°C. After 
extensive washing with water, ABTS (750 mg/liter; Boehringer Mannheim) and 0.004% H2O2 in ABTS buffer 
(pH 5.6) were added for 1 h at 37°C. Absorbances were measured at 405 nm using an automated microtiter plate 
reader (Multiscan MS, Labsystems, Zellik, Belgium). The sensitivity of this ELISA for TIMP-2 was 0.3 ng/ml, 
and the dose-response curve is linear within the 0.6-20 ng/ml range. Each sample was analysed in duplicate. 
Invasion assay.  
HT1080 cell chemoinvasion through type IV collagen (22 µg/insert) and chemotaxis were assayed using 
Transwell cell culture inserts (Costar) as previously described [27], 
Cell surface binding and degradation of 125I-TIMP-2.  
rTIMP-2 was iodinated to a specific activity of 20-40 µCi/µg using the Iodo-Gen technique (Pierce, Rockford, 
IL). Briefly, 0.8 mCi of 125I- (Na 125I, Amersham, Gent, Belgium) was added to 10 µg of rTIMP-2 in 35 µl of 0.5 
M sodium phosphate (pH 7.5). This solution was transferred into a 1.5-ml Eppendorf tube coated with 10 µg of 
Iodo-Gen. After a 2-min incubation, the reaction was blocked by transferring the reaction mixture into 0.2 ml of 
0.05 M sodium phosphate (pH 7.5). Monomeric 125I-rTIMP-2 was separated from free 125I- and potentially 
aggregated forms by filtration through a 0.9 x 50-cm column (Econo column, Bio-Rad) of S200 Sephacryl resin 
(Pharmacia, Uppsala, Sweden). Assays of 125I-rTIMP-2 binding and degradation by cells plated in 96-well plates 
(see above) were performed in triplicate as follows. After adhesion, confluent cell monolayers were 
supplemented with 125I-rTIMP-2 up to a final concentration of 0.6 nM for indicated culture periods. Nonspecific 
binding was evaluated by incubating 125I-rTIMP-2 without cells. Culture supernatants were collected after 
different incubation periods, immediately mixed with an equal volume of reducing sample buffer (with 700 nM 
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β-mercapto-ethanol), and stored at +4°C until electrophoresis. Cell monolayers were washed once with 100 µl of 
serum-free DMEM containing 0.1% BSA and extracted with 50 µl of Ripa buffer supplemented with PMSF; the 
radioactivity associated with the total cell extracts was measured in a γ-counter. Specific binding was calculated 
by subtracting the nonspecific radioactivity (wells without cells) from cell-extract-associated radioactivity. 
Results are expressed as percentages of the total radioactivity added per well. 
Polyacrylamide gel electrophoresis (PAGE).  
Samples collected from 125I-rTIMP-2 binding assays were boiled for 5 min and subjected to electrophoresis on 
SDS-15% PAGE. Once dry, gels were autora-diographied and the percentages of degraded 125I-rTIMP-2 were 
calculated based on densitometric analysis of autoradiographs. 
RESULTS 
ECM Components Modulate Pro-MMP-2 Activation 
To investigate the effect of ECM components on pro-MMP-2 synthesis and activation by HT1080 cells, 
conditioned media and total cell extracts obtained from cells cultured on plastic, type I or type IV collagen, 
laminin, or fibronectin were analyzed by gelatin zy-mography. TPA and ConA, two nonphysiological inducers 
of MMP-2 activation, were used as positive controls. 
When HT1080 cells were cultured on plastic for 24 h, conditioned medium essentially contained two gela-
tinolytic bands of 66 and 92 kDa, corresponding respectively to the MMP-2 and MMP-9 proforms (Fig. 1A, lane 
1). The corresponding cell extract yielded a major 66-kDa pro-MMP-2 and a faint 62-kDa gelatinolytic band 
(Fig. IB, lane 1). This latter band represents an intermediate activated form of MMP-2 which has been 
previously shown to result from a MT1-MMP-depen-dent proteolytic processing of pro-MMP-2 [20, 31, 32]. 
After 48 h, the amount of 62-kDa MMP-2 increased in both conditioned medium and cell extract [accounting for 
10 and 35% of total MMP-2 activity, respectively (Figs. 1A and 1B, lane 7)]. Despite its high concentration in 
the cell extract, this 62-kDa MMP-2 was not further processed to generate the fully mature 59-kDa MMP-2 
species. 
In TPA-treated (10 ng/ml) cells, the 62-kDa MMP-2 was already detectable in both conditioned medium and 
total cell extract after 24 h (Figs. 1A and 1B, lane 2). After 48 h, the secreted 62-kDa MMP-2 was slightly 
converted into the 59-kDa mature species (Fig. 1A, lane 8). TPA treatment also increased the cell-associated 
MMP-9 level (Fig. 1B, lanes 2 and 8). 
Activation of pro-MMP-2 was also strongly promoted by ConA (30 µg/ml). In contrast to TPA, ConA-treated 
cells further processed the 62-kDa intermediate MMP-2 to the fully mature 59-kDa form (Figs. 1A and 1B, lanes 
3 and 9). This ConA-mediated activation generated high levels of mature MMP-2 (about 12 and 30% of total 
MMP-2 activity after 24 h in conditioned medium and total cell extract, respectively). After a longer incubation 
(48 h), the mature 59-kDa form was the major MMP-2 species present in both conditioned medium and total cell 
extract (accounting for 45 and 50% of total MMP-2 activity, respectively) (Figs. 1A and 1B, lane 9). 
When HT1080 cells were plated on thin coats of type IV or type I collagen (20 µg/well), a faint 62-kDa 
intermediate MMP-2 form was detected in the 24-h cell extracts but not in the corresponding conditioned media 
(Figs. 1A and 1B, lanes 4 and 5). During the next 24 h, this 62-kDa band was partially converted into the 59-kDa 
form (Figs. 1A and 1B, lanes 10 and 11). Despite their similar abundance in cell extracts obtained from cells 
cultured on type IV or type I collagens (Fig. IB, lanes 10 and 11), the two activated MMP-2 forms were about 
three times more abundant in type IV than in type I collagen-derived conditioned media (Fig. 1A, lanes 10 and 
11), suggesting that the type IV collagen-induced MMP-2 activation was more efficient. 
In contrast to type IV and type I collagens, neither fibronectin (20 µg/ml, Figs. 1A and 1B, lanes 6 and 12) nor 
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Figure 1: Influence of TPA, ConA, and ECM components on pro-MMP-2 activation by HT1080 cells. Cells were 
cultured for 24 (lanes 1-6) or 48 h (lanes 7-12) on plastic without additional treatment (lanes 1 and 7), plastic 
with TPA (10 ng/ml, lanes 2 and 8), or ConA (30 µg/ml, lanes 3 and 9) treatment, type IV collagen (20 µg/well, 
lanes 4 and 10), type I collagen (20 µg/well, lanes 4 and 11), or fibronectin (20 µg/well, lanes 6 and 12). 
Conditioned media (A) and total cell extracts (B) were subjected to gelatin zymography. Scanning densitometry 
of the gels depicted in A and B was used to quantify pro-MMP-2 activation. The relative proportions of MMP-2 
activated intermediate (62-kDa; ) and mature (59-kDa; ) species are expressed as percentages of total MMP-
2. 
 
Figure 2: Influence of collagens concentration on pro-MMP-2 activation by HT1080 cells. HT1080 were 
cultured in 96 well plates coated with increasing concentrations of type IV or type I collagens (0-60 µg of 
protein/well). After 48 h, culture medium was removed and the resulting cell monolayers were washed in serum-
free DMEM, extracted in Ripa buffer, and subjected to gelatin zymogra-phy. Pro-MMP-2 activation was 
quantified after scanning densitometry of the gels. The relative proportions of activated MMP-2 forms (62 kDa + 
59 kDa) are expressed as percents of total MMP-2. 
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Type IV and Type I Collagens Promote MMP-2 Activation in a Dose-Dependent Manner 
It is now well established that the activation of pro-MMP-2 is a membrane-associated mechanism. In order to 
further characterize the influence of the ECM components on pro-MMP-2 activation, we prepared cellular 
extracts from HT1080 cells plated on increasing concentrations of type I or type IV collagens (0-60 µg/well). A 
maximal stimulation of pro-MMP-2 activation was observed for collagen concentrations ranging from 10 to 20 
µg per well. At higher concentrations, the stimulatory effect of both collagens was reduced (Fig. 2). The analysis 
of the corresponding conditioned media gave similar results (data not shown). 
The promoting effect of type IV or type I collagens on pro-MMP-2 activation was cell dependent since no 
activation was observed when supernatants of HT1080 cells plated for 48 h on plastic were further incubated for 
24 or 48 h on collagen coats (data not shown). However, it should be noted that type IV and, to a lesser extent, 
type I collagen have the ability to bind pro-MMP-2 (Fig. 3) and its two activated forms (data not shown). 
MMP Inhibitors Block Pro-MMP-2 Activation and Reduce Cell Invasiveness through Type IV Collagen 
To investigate the proteolytic process leading to pro-MMP-2 activation, HT1080 cells plated on type IV collagen 
were treated with increasing concentrations of rTIMP-2 or GI129471 (a broad-spectrum synthetic MMP 
inhibitor). rTIMP-2 dose dependently prevented the conversion of the 66-kDa pro-MMP-2 into the 62-and 59-
kDa activated forms, with inhibition of this processing being complete at 100 nM (Fig. 4A). A similar dose-
dependent blockage of pro-MMP-2 processing was observed with GI129471 (Fig. 4C), thus confirming that pro-
MMP-2 is activated through an MMP-dependent pathway. 
To determine whether this inhibition of pro-MMP-2 activation by rTIMP-2 or GI129471 influences the ability of 
HT1080 cells to invade through type IV collagen, chemoinvasion assays were performed (Figs. 4B and 4D, 
respectively). Supplementation of the culture medium with rTIMP-2 or GI129471 dose dependently inhibited the 
number of cells that breached the layer of type IV collagen and migrated to the lower side of the insert. A 
maximal 80% inhibition of HT1080 invasion was obtained with 100 nM rTIMP-2 (Fig. 4B) or 1 µM GI129471 
(Fig. 4D). It should be noted that these treatments did not significantly alter either the cellular viability (data not 
shown) nor the ability of the cells to freely migrate through uncoated inserts (as measured by the chemotaxis 
assay, Figs. 4B and 4D). These observations strongly suggest that the lower invasion extend, as measured in the 
presence of these two MMP inhibitors, most probably results from the blockage of pro-MMP-2 activation. 
 
Figure 3: Pro-MMP-2 binding to type I and type IV collagens. Conditioned medium obtained from HT1080 
cultured for 24 h on plastic was incubated in 96-well plates coated with increasing concentrations (0-20 
µg/well) of type I or type IV collagens. After 48 h, culture media were removed and ECM coats were washed in 
serum-free DMEM, extracted in Ripa buffer, and subjected to gelatin zy-mography. The amount of ECM-bound 
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Figure 4: MMP inhibitors block pro-MMP-2 activation and reduce HT1080 invasiveness through type IV 
collagen. HT1080 cells were plated on type IV collagen (20 µg/well) coats and incubated with increasing 
concentrations of rTIMP-2 (A and B) or GI129471 (C and D). Conditioned media were collected after 48 h and 
subjected to gelatin zymography (A and C). (A) HT1080 cells were cultured in the absence (lane 1; medium) or 
presence of 0.1 nM (lane 2), 1.0 nM (lane 3), 10 nM (lane 4), 100 nM (lane 5), and 1000 nM (lane 6) rTIMP-2. 
(C) HT1080 cells were treated with 10 nM (lane 2), 100 nM (lane 3), and 1000 nM (lane 4) GI129471 or vehicle 
alone (lane 1; DMSO). The influence of rTIMP-2 (B) and GI129471 (D) on HT1080 chemoinva-sion and 
chemotaxis was measured by using Transwell cell culture inserts coated or not with type IV collagen (22 
µg/insert), respectively. HT1080 cells were incubated with increasing concentrations of inhibitors and the 
number of migrated cells was determined by visually counting the number of cells present on the lower side of 
the inserts. Results are expressed as the mean ± SD percentage of the migration of control cells. *P < 0.05 
compared to controls using the Student's t test. 
 
Type IV Collagen Does Not Modify the MMP-2, MT1-MMP, or TIMP-2 mRNA Levels 
To characterize the mechanism of pro-MMP-2 processing induced by the physiological and nonphysi-ological 
activators, we investigated the influence of these inducers on MMP-2, MT1-MMP, and TIMP-2 mRNA levels. 
Total RNA obtained from HT1080 cells cultured for 4, 24, and 48 h on plastic, on type I or type IV collagen 
coats, or treated with ConA (30 µg/ml) or TPA (10 ng/ml) were analyzed by Northern blotting. These different 
treatments induced only minor alterations of MMP-2, MT1-MMP, and TIMP-2 mRNA levels (Fig. 5). Among 
these alterations, TPA transiently increased MMP-2 mRNA level after 24 h (1.6-fold increase, Fig. 5A) and 
ConA and TPA both increased the MT1-MMP mRNA level after 48 h (1.9- and 1.6-fold, respectively, Fig. 5B). 
Moreover, ConA (2.7-fold increase) and, to a lesser extent, TPA (1.8-fold increase) treatments induced a 
transient accumulation of TIMP-2 mRNA after 24 h (Fig. 5C, lanes 4 and 5). Altogether, these results showed 
that neither type I nor type IV collagens induced a marked modulation of MMP-2, MT1-MMP, or TIMP-2 
mRNA expression. 
Type IV Collagen Does Not Stimulate MT1-MMP Protein Synthesis or Activation 
Several reports have documented the involvement of MT1-MMP in pro-MMP-2 activation [22-24, 27, 31]. 
Therefore, we investigated the influence of the different MMP-2 activating treatments on both pro-MT1-MMP 
synthesis and activation (Fig. 6). When HT1080 cells were plated on plastic, three major immunoreac-tive 
proteins were detected by Western blotting of total cell extracts: a doublet composed of 63- and 66-kDa species, 
both recognized by mAb 1E12 (Fig. 6A, lane 2) and corresponding to MT1-MMP proforms [27] as well as a 60-
kDa band, revealed by mAb 2D7, corresponding to activated MT1-MMP (Fig. 6B, lane 2). Upon treatment with 
TPA, the 63-kDa pro-MT1-MMP level was slightly increased (Fig. 6A, lane 3). Moreover, an additional 43-kDa 
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band, which was recognized by mAb 2D7, was detected (Fig. 6B, lane 3). This latter MT1-MMP species was 
recently identified as a cell-surface-associated inactive form which results from an MMP-dependent processing 
of the 60-kDa form and whose occurrence was related to pro-MMP-2 activation [13, 52]. In contrast to TPA, 
ConA did not increase the level of the 63-kDa pro-MT1-MMP but it dramatically increased both 60- and 43-kDa 
species (Figs. 6A and 6B, lane 4). When total cell extracts obtained from HT1080 cells plated on ECM 
components (type I or type IV collagens or fibronectin) were analyzed, no significant qualitative nor quantitative 
modification of MT1-MMP synthesis or processing was observed (Figs. 6A and 6B, lanes 5-7). It should be 
noted that the extracts obtained from HT1080 cells plated on plastic and the ECM components also contain the 
43-kDa MT1-MMP but at a very low levels [27]. 
 
Figure 5: Influence of TPA, ConA, and ECM components on MMP-2 (A), MT1-MMP (B), and TIMP-2 (C) 
steady-state mRNA levels. HT1080 cells were plated on plastic or type I (Col I) and type IV (Col IV) collagen 
coats (20 µg/well) or treated with ConA (ConA, 30 µg/ml) or TPA (TPA, 10 ng/ml) for 4 ,24 , or 48 h. 
Total RNA (10 µg) was electrophoresed, blotted, and hybridized as described under Materials and Methods. 
Levels of the different transcripts were quantified by densitometric analysis of the autoradiographs of the 
Northern blots. All results were corrected for RNA loading using densitometric data obtained for the 28S-rRNA. 
Results are expressed as the ratio of the optical density (OD) of each tran-script/OD of 28S-rRNA. 
 
Figure 6: Influence of TPA, ConA, and ECM components on MT1-MMP synthesis and processing. HT1080 cells 
were cultured for 48 h on plastic (lane 2), type IV collagen (20 µg/well, lane 5), type I collagen (20 µg/well, lane 
6), or fibronectin (20 µg/well, lane 7) or treated with TPA (10 ng/ml, lane 3) or ConA (30 µg/ml, lane 4). Total 
cell extracts were subjected to Western blotting using mAb IE 12 directed against the MT1-MMP prodomain (A) 
and mAb 2D7 directed against the MT1-MMP hemopexin-like domain (B). Extracts from COS-1 cells transiently 
transfected to overexpress MT1-MMP (COS-MT1) were used as a positive control (lane 1). 
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Type IV Collagen Reduces TIMP-2 Concentration in HT1080 Conditioned Medium 
TIMP-2 has previously been demonstrated to play a dual role in pro-MMP-2 activation: at low concentrations, it 
promotes activation while, at higher concentrations, it completely inhibits this process [20, 28, 53]. To detect a 
potential modification of TIMP-2 concentration induced by pro-MMP-2 activating treatments, TIMP-2 
concentrations in conditioned media and total cell extracts were quantified by ELISA (Fig. 7). When HT1080 
cells were plated on plastic, the evolution of TIMP-2 concentration in conditioned medium was bi-phasic: it 
increased during the first 24 h, reaching about 3.5 ng/well, and then slightly decreased during the next 24 h. In 
contrast, TIMP-2 concentration in total cell extract was low throughout the culture period (Fig. 7A). Culturing 
the cells on type I collagen (20 µg/well, Fig. 7B) or fibronectin (20 µg/well, Fig. 7C) did not significantly 
modify the TIMP-2 secretion profile observed on plastic (Fig. 6A). In contrast, TPA (10 ng/ml, Fig. 7D), ConA 
(30 µg/ml, Fig. 7E), and type IV collagen (20 µg/well, Fig. 7F) treatments dramatically altered this profile. 
Upon treatment with TPA, TIMP-2 concentration in conditioned medium increased steadily but remained low 
throughout the 48-h period (Fig. 7D). In contrast, ConA treatment induced a marked modification of TIMP-2 
partitioning between conditioned medium and cell extract (Fig. 7E). Indeed, while the sum of conditioned-
medium- and cell-extract-associated TIMP-2 was similar to that measured on plastic, TIMP-2 concentration in 
conditioned medium decreased in favor of cell extract. In the presence of type IV collagen (Fig. 7F), TIMP-2 
secretion in conditioned medium displayed a similar evolution to that observed on plastic; however, TIMP-2 
concentrations were about 2x lower than on plastic (2.5 and 1 ng/well, respectively, after 48 h). In contrast, type 
IV collagen-derived cell extract contained only slightly more TIMP-2 than plastic-derived one (Fig. 7F). 
When HT1080 cells were plated on increasing concentrations of type IV collagen (0-60 µg/well), TIMP-2 
secretion dose dependently decreased up to 20 µg of type IV collagen/well and then slightly increased (Fig. 8). 
In contrast, neither type I collagen nor fibronectin was able to induce any modulation of TIMP-2 secretion (data 
not shown). 
 
Figure 7: Modulation of TIMP-2 concentration in conditioned media and total cell extracts of HT1080 cells 
plated on ECM components or treated with either TPA or ConA. HT1080 cells were cultured for 6, 24, and 48 h 
on plastic (A), type I collagen (20 µg/well, B), type IV collagen (20 µg/well, F), fibronectin (20 µg/well, C), or 
treated with TPA (10 ng/ml, D) or ConA (30 µg/ml, E). TIMP-2 concentrations in conditioned media and total 
cell extracts were quantified by ELISA. Results are expressed as the mean ± SD amount of TIMP-2 measured in 
conditioned media (CM, ), cell extracts (CE, ), and total TIMP-2 (sum of TIMP-2 concentrations detected in 
both conditioned media and cell extracts, CM + CE, ). 
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Figure 8: Dose-dependent modulation of TIMP-2 concentrations by type IV collagen. TIMP-2 concentration in 
conditioned medium of HT1080 cells cultured for 48 h on increasing concentrations (0-60 µg/well) of type IV 
collagen was quantified by ELISA. Results are expressed as the mean ± SD TIMP-2 concentrations. 
 
Type IV Collagen Increases TIMP-2 Degradation 
In a previous study, we demonstrated that TPA treatment of HT1080 cells stimulated the internalization and 
degradation of TIMP-2 through a MT1-MMP-dependent mechanism, resulting in a lower level of secreted 
TIMP-2 [54]. To investigate the potential occurrence of a similar degradation in the presence of type IV 
collagen, we compared the fate of 125I-rTIMP-2 (0.6 nM) added to HT1080 cells cultured for up to 48 h on 
plastic or type IV collagen (20 µg/well). Culture supernatants and cell monolayers were collected at different 
times and subjected to SDS-PAGE and γ-counting, respectively (Figs. 9A-9C). When 125I-rTIMP-2 was 
incubated alone, SDS-PAGE analysis revealed the presence of a single band of an apparent molecular mass of 
about 21 kDa corresponding to the intact inhibitor (Fig. 9A). When 125I-rTIMP-2 was incubated with HT1080 
cells plated on plastic or type IV collagen, the intensity of the 21-kDa band decreased concomitantly with the 
appearance of an additional band, migrating just above the dye migration front (Fig. 9A). We have previously 
demonstrated that this low-molecular-weight band represents 125I-bearing peptide (s) resulting from the 
degradation of 125I-TIMP-2 [54]. Quantification of degraded 125I-rTIMP-2 by scanning densitometry of the 
autoradiographs revealed that HT1080 cells plated on type IV collagen degraded 2x more 125I-rTIMP-2 than 
those plated on plastic (Fig. 9B). After 48 h on type IV collagen, up to 65% of 125I-rTIMP-2 was degraded. 
Quantification of cell-bound 125I-rTIMP-2 by γ-counting indicated that about 1% of the exogenously added 125I-
rTIMP-2 bound to HT1080 cells plated on plastic (Fig. 9C). In the presence of type IV collagen, the percentage 
of cell bound 125I-rTIMP-2 reached 5%, thereby demonstrating that the lower level of secreted TIMP-2 measured 
by ELISA (Fig. 7F) results from its binding to the cell surface and more importantly from its degradation. 
Type IV Collagen-Mediated TIMP-2 Degradation Is Inhibited by a Synthetic MMP Inhibitor 
Because TIMP-2 was shown to bind to the cell surface by interacting with the active site of MT1-MMP [28, 30], 
we examined the influence of GI129471 on type IV collagen-stimulated TIMP-2 binding and degradation by 
HT1080 cells. Such synthetic inhibitors have previously been shown to bind to the active site of MMPs [55], 
thus competing with TIMP-2 for binding to MT1-MMP [28, 33, 54]. HT1080 cells plated on type IV collagen 
were incubated for up to 48 h with or without 1 µM GI129471 and TIMP-2 concentrations in conditioned media 
and total cell extracts were determined by ELISA (Fig. 9D). In the presence of GI129471, cell-associated TIMP-
2 level was reduced (Fig. 9D, inset) concomitant with a dramatic increase in TIMP-2 level in the conditioned 
medium. However, this slightly reduced TIMP-2 binding is not sufficient to account for the fivefold increase in 
TIMP-2 concentration in the conditioned medium, therefore supporting an inhibition of the type IV collagen-
stimulated TIMP-2 degradation by GI129471. 
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Figure 9: Degradation and binding of TIMP-2 by HT1080 cells. 125I-rTIMP-2 was added to cell-free culture 
medium (Med) or HT1080 cells plated on plastic (Plast) or type IV collagen (Col IV, 20 µg/well). After 24 and 
48 h, conditioned media and total cell extracts were collected and subjected to SDS-PAGE (A and B) and γ-
counting (C). (A) Conditioned media harvested after 24 h were subjected to SDS-15% PAGE followed by 
autoradiography of the gel. Arrow, intact 125I-rTIMP-2; arrowhead, degraded 125I-rTIMP-2. (B) Percentages of 
degraded 125I-rTIMP-2 were calculated after scanning densitometry of the autoradiographs of conditioned 
media harvested after 24 and 48 h. (C) 125I-rTIMP-2 binding to HT1080 cells after 24 and 48 h was quantified 
by measuring total cell-extract-associated radioactivity. Specific binding was calculated as the difference 
between bound radioactivity in the presence and in the absence of cells (nonspecific). Results are expressed as 
the mean ± SD % of 125I-rTIMP-2 concentrations. (D) HT1080 cells plated on type IV collagen were treated for 
up to 48 h with or without 1 µM GI129471. TIMP-2 concentrations in the conditioned media (CM) and total 
cell extracts (CE, inset) were assessed by ELISA. 
 
DISCUSSION 
In the present study, we investigated the potential influence of ECM components on pro-MMP-2 activation by 
HT1080 cells, a human fibrosarcoma cell line. This ECM-mediated activation was compared with the processing 
induced by two previously described non-physiological MMP-2 activators: TPA and ConA. 
MMP-2 Activation by TPA- and ConA-Treated HT1080 Cells 
When HT1080 cells were plated on plastic, zymo-graphic analysis revealed that MMP-2 was essentially secreted 
in an inactive 66-kDa proform. Nevertheless, the presence of 62-kDa intermediate MMP-2 form as well as the 
detection by Western blotting of some activated (60 kDa) MT1-MMP in cell extract suggests that, under basal 
conditions, HT1080 cells are constitutively able to perform the first MT1-MMP-dependent step of pro-MMP-2 
activation. It should be noted that the appearance of this intermediate MMP-2 form coincides with a slight 
decrease of TIMP-2 secretion and the parallel increase of cell-bound TIMP-2 (Fig. 7A). These data are in 
agreement with previous observations that cell-associated TIMP-2 is required for pro-MMP-2 activation [20, 28, 
53]. 
As previously reported by others [6, 13, 15, 56-58], we showed that TPA- or ConA-treated HT1080 cells 
increased MT1-MMP mRNA expression and substantially upregulated MT1-MMP protein synthesis. 
Furthermore, both treatments induced the formation of a 43-kDa MT1-MMP species (Figs. 6A and 6B, lanes 2-
4). The occurrence of this latter form has been associated with the ability of the cells to activate MMP-2 and to 
degrade gelatin [13, 29, 59]. Consistent with these data, our results also demonstrated an obvious association 
Published in: Experimental Cell Research (2000), vol. 261, iss. 2, pp. 348-59 
Status: Postprint (Author’s version) 
 
between the TPA- and ConA-induced pro-MMP-2 activation and MT1-MMP processing into a 43-kDa form. 
Indeed, the level of the 43-kDa species more precisely correlates with the appearance of the fully mature 59-kDa 
MMP-2 form (compare Fig. 1A, lanes 7-9, and Fig. 6B, lanes 2-4). In this respect, it is interesting to note that 
even if both TPA and ConA treatments induced the formation of the 62-kDa intermediate MMP-2, only ConA 
efficiently converted this intermediate into the mature 59-kDa form, as previously reported by Gervasi and co-
workers [56]. The ability of ConA to promote the second step of MMP-2 activation (i.e., the intermolecular 
autolytic cleavage) has been ascribed, at least in part, to its potential to cluster membrane glycoproteins, 
including MT1-MMP, thereby favoring the autoproteolytic processing of adjacent MT1-MMP-associated 
intermediate MMP-2 species [56, 60, 61]. 
Type IV Collagen Induces the Formation of Mature 59-kDa MMP-2 
When HT1080 cells were plated in contact with different ECM proteins, pro-MMP-2 activation was only 
stimulated by type I or type IV collagens. Indeed, while fibronectin and laminin failed to modulate the MMP-2 
activation observed on plastic, type I and type IV collagens induced the processing of the intermediate MMP-2 
form to the fully mature 59-kDa species. Our experimental data contrast with the results of Stanton and co-
workers reporting that the culture of HT1080 cells on fibronectin (but not laminin) promoted pro-MMP-2 
activation [62]. This discrepancy might be a consequence of some clonal modifications of the cellular phenotype 
of this cell line. In agreement with this hypothesis, it is worth noting that Stanton and coworkers reported that 
HT1080 cells treated with phor-bol ester processed pro-MMP-2 into the 59-kDa fully mature form. In our cell 
culture model, and in agreement with others [56], a similar treatment promoted the generation of the 62-kDa 
intermediate MMP-2 species without any significant further conversion into the mature form. 
Compared to the nonphysiological activators mentioned above, collagen-mediated MMP-2 processing required 
longer incubation periods and did not involve any transcriptional modulation of MMP-2, MT1-MMP, or TIMP-2 
expression. We previously demonstrated that, in HT1080 cells, the type IV collagen-mediated pro-MMP-2 
activation into the 59-kDa mature form was associated with the level of 60-kDa active MT1-MMP species [27]. 
However, neither type I nor type IV collagens were able to modify the MT1-MMP synthesis or activation 
observed in cells plated on plastic (Figs. 6A and 6B, lanes 2, 5, and 6). This observation strongly suggests that, 
in addition to active 60-kDa MT1-MMP, other factor(s) are required to fully activate pro-MMP-2. 
Relationship between TIMP-2 Concentration in the Conditioned Medium and Pro-MMP-2 Activation 
On the basis of the dual role of TIMP-2 during MMP-2 activation, promoting MMP-2 activation when present at 
low concentrations [20, 29, 31, 54, 63, 64], but acting as an efficient inhibitor of this process when present at 
higher doses [19, 20, 26, 31, 53, 65-67], we hypothesized that modulations of TIMP-2 concentration could play 
important roles in the regulation of MMP-2 processing. Consequently, we investigated the modifications of both 
TIMP-2 concentration and distribution between conditioned media and cell extracts induced by MMP-2-
activating treatments. In agreement with recently published data [29, 30], the lower level of secreted TIMP-2, 
together with the sharply increased cell-associated TIMP-2 concentration observed in ConA-treated HT1080 
cells (Fig. 7E) suggests that ConA, by increasing MT1-MMP activation (Fig. 6B, lane 4), triggers the docking of 
secreted TIMP-2 to the cell surface. In contrast, TPA treatment dramatically decreased the level of secreted 
TIMP-2 without significantly stimulating its binding to the cell surface (Fig. 7D). We recently demonstrated that 
this low concentration of secreted TIMP-2 resulted from an MT1-MMP-dependent internalization of TIMP-2 
associated with an intracellular degradation process [54]. When HT1080 cells were plated on type IV collagen, 
the cell-associated TIMP-2 concentration was slightly increased (Figs. 7F and 9C). However, this increase was 
not sufficient to account for the sharply decreased concentration of TIMP-2 in the conditioned medium. We 
demonstrated here that this decreased level of secreted TIMP-2 essentially results from an enhanced degradation 
of TIMP-2 triggered by type IV collagen (Fig. 9B). Interestingly, the concentration of TIMP-2 in conditioned 
media is modulated by the amount of coated type IV collagen (Fig. 8) and is inversely related to the extent of 
MMP-2 activation (compare Figs. 8 and 2). Whether this modulation of TIMP-2 concentration is a cause or a 
consequence of MMP-2 activation remains to be elucidated. 
MMP-2 Activation by Type TV Collagen: A Hypothetical Mechanism 
The stimulation of MMP-2 activation induced by type IV collagen displayed a bell-shaped dose-response curve: 
increasing for collagen concentrations ranging from 1 to 10 µg and then progressively decreasing at higher 
concentrations (Fig. 2). Interestingly, a similar dose-dependent modulation of MMP-2 activation has previously 
been reported with heparin [68]. Due to its ability to bind MMP-2, heparin promotes the intermolecular MMP-2 
autocatalytic cleavage by bringing closer MMP-2 molecules present in solution. It is therefore tempting to 
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speculate that, in our culture model, collagen molecules can have a similar function. Indeed, in agreement with 
our observations (Fig. 3), Allan and co-workers [69] demonstrated that both pro- and active MMP-2 efficiently 
bind to thin coats of type I and type IV collagens, but very poorly to fibronectin. This collagen-binding property 
is solely mediated by the fi-bronectin-type II inserts present in the catalytic domain of the enzyme [69]. As a 
consequence, the interaction of cell surface anchored MMP-2 with the molecules of type IV collagen is likely to 
induce the clustering of the MT1-MMP/TIMP-2/MMP-2 ternary complexes at the sites of interaction with the 
ECM, therefore promoting the intermolecular autocatalytic cleavage required to generate fully mature MMP-2. 
Alternatively, the transmembrane/cytoplasmic domain of MT1-MMP was previously shown to mediate its 
localization in invadopodia (specialized membrane extensions present at the sites where invading cells are in 
close contact with the ECM) where it can interact with several other proteins including integrins [61, 70]. 
Consequently, binding of HT1080 cells to collagen molecules via members of the integrin family could trigger 
the clustering of invadopodia-associated MT1-MMPs therefore promoting MMP-2 maturation. Interestingly, 
increasing concentrations of ECM components have been shown to enhance integrin binding and clustering, 
leading to a progressive decrease of MMP-2 activation by human capillary endothelial cells (Yan et al., personal 
communication). A similar mechanism is probably responsible for the lower MMP-2 activation observed here in 
the presence of high collagen concentrations (Fig. 2). 
Type IV Collagen-Mediated MMP-2 Activation Is Associated with Invasion of HT1080 Cells 
We have previously demonstrated that active MMP-2 was required for HT1080 cells to invade through type IV 
collagen coated Transwell cell culture inserts [27]. By using a similar in vitro invasion model, we demonstrated 
here a close association between the inhibition of both chemoinvasion and pro-MMP-2 activation by rTIMP-2 or 
GI129471 (Fig. 8), strongly suggesting that this type IV collagen-mediated pro-MMP-2 activation might 
represent a physiologically relevant system. This observation contrasts with the effect of ConA which, despite its 
high efficiency to promote pro-MMP-2 activation, failed to induce both degradation and invasion of the ECM 
[61]. 
Altogether, these data suggest that, in contrast to the previously published mechanisms accounting for the 
induction of MMP-2 activation by ECM components [42-44, 62], the promoting effect of type IV collagen does 
involve neither an upregulation of MT1-MMP transcription nor a posttranslational modification of MT1-MMP. 
It can be hypothesized that type IV collagen mediates its effect by bringing closer cell membrane-associated 
MT1-MMP/TIMP-2/MMP-2 complexes, therefore promoting the intermolecular autolytic cleavage of 
intermediate MMP-2 and thus leading to the generation of the fully mature species. Additionally, type IV 
collagen decreases the level of secreted TIMP-2, thus potentially furthering the processing of pro-MMP-2 which 
is known to be inhibited by high TIMP-2 concentrations [20, 31, 53]. It is worth noting that the TIMP-2 
degradation process illustrated here potentially represents an additional regulatory mechanism of the proteolytic 
activity of the cells. Indeed, because the net proteolytic activity reflects the balance between the levels of active 
proteinases and their corresponding inhibitors [71], the ability of HT1080 cells to degrade TIMP-2 when plated 
on type IV collagen might alter this balance and, consequently, increase their degradative capacity. Conversely, 
the accumulation of secreted TIMP-2 observed in the presence of the synthetic MMP inhibitor (Fig. 9D) might 
contribute to the anti-invasive property of this compound (Fig. 4D). 
Gilles and co-workers [72] have previously reported that the activation of pro-MMP-2 by two breast carcinoma 
cell lines was stimulated in the presence of SPARC (secreted protein acidic and rich in cystein)/ osteonectin. 
Interestingly, this activation did altered neither MT1-MMP mRNA nor protein levels but it was clearly 
associated with a significant decrease of the level of secreted TIMP-2, suggesting the occurrence of an activation 
mechanism similar to that induced by type IV collagen in this study. 
In conclusion, our results reveal that the interactions between type IV collagen and human fibrosarcoma cells 
result in the activation of pro-MMP-2 at the cell surface. As invasive tumor cells must breach BMs at different 
steps of the metastatic dissemination, the ability of HT1080 cells to activate MMP-2 (a major type IV 
collagenase) when they encounter type IV collagen might thus represent a key regulatory mechanism for the 
acquisition of an invasive potential. Whether a similar stimulation of MMP-2 activation by type IV collagen also 
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